Spotlight on Pfizer: Analyzing the Surge in Options Activity

Whales with a lot of money to spend have taken a noticeably bearish stance on Pfizer.

Looking at options history for Pfizer PFE we detected 27 trades.

If we consider the specifics of each trade, it is accurate to state that 29% of the investors opened trades with bullish expectations and 59% with bearish.

From the overall spotted trades, 12 are puts, for a total amount of $634,798 and 15, calls, for a total amount of $760,655.

Expected Price Movements

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $15.0 and $32.5 for Pfizer, spanning the last three months.

Analyzing Volume & Open Interest

Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Pfizer's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Pfizer's significant trades, within a strike price range of $15.0 to $32.5, over the past month.

Pfizer Option Activity Analysis: Last 30 Days

Significant Options Trades Detected:

About Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

After a thorough review of the options trading surrounding Pfizer, we move to examine the company in more detail. This includes an assessment of its current market status and performance.

Pfizer's Current Market Status

• With a volume of 46,638,429, the price of PFE is up 1.15% at $28.17.
• RSI indicators hint that the underlying stock may be approaching overbought.
• Next earnings are expected to be released in 82 days.

Professional Analyst Ratings for Pfizer

Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $38.75.

• Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $45.
• An analyst from BMO Capital has revised its rating downward to Outperform, adjusting the price target to $36.
• An analyst from Morgan Stanley persists with their Equal-Weight rating on Pfizer, maintaining a target price of $29.
• Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $45.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Pfizer, Benzinga Pro gives you real-time options trades alerts.